2020
Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, Carney M, Jensen A, Cramer D, Berchuck A, Doherty J, Modugno F, Goodman M, Alimujiang A, Rossing M, Cushing-Haugen K, Bandera E, Thompson P, Kjaer S, Hogdall E, Webb P, Huntsman D, Moysich K, Lurie G, Ness R, Stram D, Roman L, Pike M, Pearce C. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31: 402-408. PMID: 32028322, PMCID: PMC7584395, DOI: 10.1097/ede.0000000000001175.Peer-Reviewed Original ResearchConceptsRisk of ovarian cancerEstrogen-progestin combined therapyEstrogen-alone therapyAssociated with increased riskOvarian cancerCombination therapyRisk of ovarian cancer overallAssociated with increased risk of ovarian cancerOvarian cancer risk factorsPopulation-based case-control studyOvarian Cancer Association ConsortiumMenopausal hormone therapy useIncreased risk of endometrial cancerOvarian cancer overallRisk of endometrial cancerCancer risk factorsHistotypes of ovarian cancerRisk factorsProgestin hormone therapyMucinous ovarian cancerOvarian cancer casesIn-person interviewsHormone therapy useOvarian cancer histotypesCase-control study
2019
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Kim S, Wang M, Tyrer J, Jensen A, Wiensch A, Liu G, Lee A, Ness R, Salvatore M, Tworoger S, Whittemore A, Anton‐Culver H, Sieh W, Olson S, Berchuck A, Goode E, Goodman M, Doherty J, Chenevix‐Trench G, Rossing M, Webb P, Giles G, Terry K, Ziogas A, Fortner R, Menon U, Gayther S, Wu A, Song H, Brooks‐Wilson A, Bandera E, Cook L, Cramer D, Milne R, Winham S, Kjaer S, Modugno F, Thompson P, Chang‐Claude J, Harris H, Schildkraut J, Le N, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike M, Pharoah P, Pearce C, Mukherjee B. A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants. International Journal Of Cancer 2019, 144: 2192-2205. PMID: 30499236, PMCID: PMC6399057, DOI: 10.1002/ijc.32029.Peer-Reviewed Original ResearchConceptsOral contraceptive pill useExcess risk due to additive interactionOvarian cancer risk factorsOral contraceptive pillsGene-environment interaction analysisCancer risk factorsGene-environment analysisOvarian cancer casesOCP useCase-control studyGenome-wide association analysisAdditive scaleCancer casesOvarian cancerOdds ratioCommon variantsDuration of OCP useRisk allelesRisk factorsGenetic variantsAdditive interactionAssociation analysisWomenFollow-upC allele